NCT07455032
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07455032
Title Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.